James R. Gruber CPA Net Worth

Mr. James R. Gruber CPA biography

James R. Gruber CPA is the CFO, Treasurer & Sec. at Eton Pharmaceuticals.

How old is Mr CPA?

Mr CPA is 49, he's been the CFO und Treasurer & Sec. of Eton Pharmaceuticals since . There are 5 older and 2 younger executives at Eton Pharmaceuticals. The oldest executive at Eton Pharmaceuticals, Inc. is Charles Casamento, 75, who is the Independent Director.

What's Mr CPA's mailing address?

James's mailing address filed with the SEC is C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK, IL, 60010-7208.

Insiders trading at Eton Pharmaceuticals

Over the last 6 years, insiders at Eton Pharmaceuticals have traded over $20,773,599 worth of Eton Pharmaceuticals stock and bought 488,500 units worth $3,287,585 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum und Health, Inc. Harrow. On average, Eton Pharmaceuticals executives and independent directors trade stock every 61 days with the average trade being worth of $746,905. The most recent stock trade was executed by Sean Brynjelsen on 22 September 2022, trading 10,000 units of ETON stock currently worth $21,000.

What does Eton Pharmaceuticals do?

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals executives and stock owners

Eton Pharmaceuticals executives and other stock owners filed with the SEC include:

• Sean Brynjelsen,
  President, Chief Executive Officer, Director
• W. Troutman,
  Chief Financial Officer, Treasurer, Secretary
• Sean E. Brynjelsen,
  Pres, CEO & Director
• W. Wilson Troutman CPA,
  CFO, Treasurer & Sec.
• Norbert Riedel,
  Independent Chairman of the Board
• Paul Maier,
  Independent Director
• Charles Casamento,
  Independent Director
• Mark Baum,
  Director
• Ingrid Hoos,
  Senior Vice President - Scientific Affairs
• Kevin Guthrie,
  Exec. VP of Commercial Operations
• James R. Gruber CPA,
  CFO, Treasurer & Sec.
• David Krempa,
  VP of Bus. Devel.
• Scott Grossenbach,
  VP of Sales & Marketing
• Bharathi Devarakonda,
  Sr. VP of Regulatory Affairs & Product Devel.
• Paul Stickler,
  Sr. VP of Sales & Marketing
• Health, Inc. Harrow,
  10% owner
• James R. Gruber,
  Chief Financial Officer
• Management Inc. Opaleye,
  10% owner
• Jennifer Mc Kie Adams,
  Director
• David Krempa,
  Chief Business Officer